newsfilter
← Earnings
Earnings Releases·

Agios Pharmaceuticals — Third Quarter 2026 Earnings Summary

  • Net product revenue surged to $55.4 million in Q3 2026, a more than fourfold increase from $12.9 million in Q3 2025, while the net loss narrowed to $65.0 million from $103.4 million year-over-year.
  • The company targets non-GAAP profitability in 2028 and anticipates realizing cost savings from R&D headcount reductions (over 100 roles) in 2027, supported by a cash position of $907.0 million.
  • The PDUFA goal date for the mitapivat sickle cell disease sNDA is set for February 1, 2027, following a three-month regulatory extension due to a REMS inquiry.
  • Mitapivat remains the primary revenue driver with U.S. sales up 20% sequentially and ex-U.S. revenue up 74% sequentially, driven by EU approvals and early access programs.
Company
AGIOS PHARMACEUTICALS INC
Sector
Healthcare
Industry
Biotechnology